BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Bogdana Schmidt
Yeah, so just to quickly introduce Sunrise for kind of the concept. So this was the muscle invasive patients who were chemo ineligible or refusing, who got TAR200 plus citrelumab versus citrelumab monotherapy. And this was in that five to three randomization that maybe we can talk about a little bit. Those patients then went on to get radical cystectomy.
0
💬
0
Comments
Log in to comment.
There are no comments yet.